ISO ISMPOCON 2025, Jaipur "Winning the Battle Against Cancer- From Insights to Impact!"  Saturday - Day 2 - 01st November 2025		
	Hall D - Skill East NK Block	
2:30 PM - 5:30 PM	ISMPO Free Papers Session (6 Min Each Presenter) - 28 Presentations	
2.30 1 101 3.30 1 101	ISWI OTTECT upon Session (OTMIT Edent Tesenter) 20 Tresentations	
Session Coordinator	Dr. Supreeth RN & Dr. Nihanty Sreenath	
36331011 600141114101	Si. Suprecti in a Si. Minanty Sicendari	
Judges	Dr. N K Warrier, Kozhikode; Dr. Krishna Kumar Rathnam, Madurai	
Judges	DI. 14 K Warriel, Rozinkode, Di. Kristina Kamar Katmani, Wadarai	
2.20 DN4 2.20 DN4	Con Assist Bussets India/s solution to proposation in LIB. /LIBBS FDC nationts	
2:30 PM - 2:36 PM	CanAssist Breast: India's solution to prognostication in HR+/HER2- EBC patients	
Presenter	Dr. Tejal Deepak Durgekar, Bengaluru	
2:36 PM - 2:42 PM	A New Risk Assessment Tool for Prognostic Classification in Newly Diagnosed Stage IV Breast Cancer: Insights	
	from a Tertiary Cancer Center in Northeast India	
Presenter	Dr. Manas Dubey, Prayagraj	
2:42 PM - 2:48 PM	Concerns regarding fertility and other psychosocial issues faced by Adolescents and Young Adults receiving	
21.21.11. 21.101.11.	chemotherapy in a South Indian Tertiary cancer center	
Presenter	Dr Ananda N S, Bengaluru	
2:48 PM - 2:54 PM	Immune checkpoint inhibitors (ICIs) in deficient mismatch repair (dMMR)/ microsatellite instability (MSI) non-colorectal cancers –real world Indian data and the use of alternative dosing	
Presenter	Dr. Dishant Vaddoriya, Ahmedabad	
2:54 PM - 3:00 PM	Perioperative FLOT in Gastric and GEJ Adenocarcinoma: Real-World Outcomes from Northeast India	
Presenter	Dr Hemant Kumar Mittal, Guwahati	
3:00 PM - 3:06 PM	Low-dose versus standard-dose abiraterone in patients with metastatic castration resistant prostate cancer - a multicentric randomized phase III trial	
Presenter	Dr Minit Shah, Mumbai	
3:06 PM - 3:12 PM	Adequacy of combination of nivolumab + cabozantinib in metastatic clear renal cell carcinoma – a retrospective analysis at a tertiary care center	
Presenter	Dr. Shiv Ghodasara, Udaipur	
3:12 PM - 3:18 PM	Efficacy of Maintenance Avelumab Therapy in Patients with Locally Advanced/Metastatic Urothelial Cancer: A Real-World Indian Study	
Presenter	Dr Ankur Mudgal, Gurugram	
3:18 PM - 3:24 PM	Maintenance PARP inhibitors in patients with Ovarian Cancer: A Real-world- single center experience.	
Presenter	Dr Vineetha Rijju, Kozhikode	
escriter	- · · · · · · · · · · · · · · · · · · ·	
3:24 PM - 3:30 PM	Assessing Changes in Tumor Burden and Early Tumor Shrinkage with Cetuximab-Based Regimen in R/M SCCHN: A Retrospective Analysis	
Presenter	Dr. Siddhesh Tryambake, Hyderabad	
Judges	Dr. TVS Tilak, Delhi ; Dr. Vinayaka Maka, Bengaluru	

3:30 PM - 3:36 PM	Redox-Linked Alterations in Immune and Oncogenic Pathways in T-ALL: Evidence from a Case–Control Stud
Presenter	Dr. Sandeep Pandey, Lucknow
riesentei	DI. Sandeep Fandey, Edeknow
3:36 PM - 3:42 PM	Clinicopathological features and molecular predictors of outcomes in adolescents and young adults with acute myeloid leukaemia.
Presenter	Dr Abhigyna Gauri Oruganty, Hyderabad
3:42 PM - 3:48 PM	Real world Indian data on Glofitamab for relapsed or refractory high-grade B-cell non-hodgkin's lymphom insights to digest the BiTE
Presenter	Dr. Saswata Saha, Kolkata
3:48 PM - 3:54 PM	Novel Low-Cost CBC-Derived Parameters to Predict CD34+ Yield Adequacy in Adult Autologous hematopoietic Stem cell Transplantation: A Retrospective Derivation Study from India
Presenter	Dr Ananda N S, Bengaluru
3:54 PM - 4:00 PM	Role of Granulocyte transfusions in life-threatening neutropenic sepsis: Experience from a tertiary care center in South India
Presenter	Dr. Arjun Mandade, Bengaluru
4:00 PM - 4:06 PM	Circulating Immunomarkers and Their Predictive Value for Survival in Hepatocellular Carcinoma Undergoid Immunotherapy - Data from a Tertiary Cancer Institute in South India
Presenter	Dr Abhijith P B, Kozhikode
4:06 PM - 4:12 PM	Claudin 18.2–Targeted CAR T Therapy in Refractory Siewert Type III Gastroesophageal Junction Adenocarcinoma
Presenter	Dr. B. Sai Sree Reddy, Hyderabad
4:12 PM - 4:18 PM	Autologous Hematopoietic Stem Cell Transplantation in Childhood Lymphoma: Single-Institution Outcome from India
Presenter	Dr. Padmapriya T V, Chennai
4:18 PM - 4:24 PM	Long-term outcomes with tepotinib for clinically relevant subgroups of patients with MET exon 14 (METex14) skipping NSCLC in the VISION study: A ≥3-year follow-up
Presenter	Dr. Vaibhav Saxena, Mumbai
4:24 PM - 4:30 PM	Seven-Year Trends in Histology, Molecular Testing, Fusion Variants, and Outcomes in Metastatic ALK-Positi NSCLC: A Single-Centre Indian Experience
Presenter	Dr Jyothis P Jose, Kozhikode
Judges	Dr. Bhawna Sirohi, Raipur ; Dr. Vikas Talreja, Kanpur
·	
4:30 PM - 4:36 PM	Prevalence of DPYD variants and toxicity profile in patients receiving fluoropyrimidines at a tertiary cance center in India
Presenter	Dr Devarakonda Srujana, Bengaluru
4:36 PM - 4:42 PM	Incidence and risk factors for reduced DLCO in Survivors of childhood cancer: A report from a single centr from LMIC
Presenter	Dr Radha Bhardwaj, Delhi
4:42 PM - 4:48 PM	To see the early effects of sorafenib on cognition, cardiovascular and reproductive functions in patients w fibromatosis.

Presenter	Dr. Akash Singh, Delhi
4:48 PM - 4:54 PM	Nutritional risk assessment and quality of life in patients receiving chemotherapy in elderly patients in a tertiary care centre
Presenter	Dr. Papareddy Abhinaya, Chennai
4:54 PM - 5:00 PM	SpHeRe 1.0 (Spiritual Health Reflection): Mapping Inner Well-being in Oncology Healthcare Workers from Tier II Cancer Care Centre in Southern Tamil Nadu, India – A Mixed Method Pilot Study.
Presenter	Dr. Gokula Krishnan, Madurai
5:00 PM - 5:06 PM	"MIND & MONEY" - Impact of a Structured Assessment Tool & Targeted Referral on Psychosocial & Financia Distress in Outpatients with Advanced Cancer
Presenter	Dr. Praveen Kumar Marimuthu, Vellore
5:06 PM - 5:12 PM	Comparison of Dexamethasone sparing regimen with NEPA (Netupitant/Palonosetron) versus  Dexamethasone containing antiemetic therapy for prevention of chemotherapy induced nausea and vomiting in breast cancer patients receiving anthracycline and cyclophosphamide chemotherapy.
Presenter	Dr. Tarun Tomar, Udupi